Ultimately, by bridging the gap between metabolic dysfunction and mood disorders, adiponectin may pave the way toward a new generation of “metabocentric” therapies that expand our approach to treating depression and related conditions. This evidence concerns the gene ADIPOQ and depressive disorder.